Immuneering (IMRX) Competitors

Candel Therapeutics (NASDAQ:CADL) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.

Do institutionals & insiders hold more shares of CADL or IMRX?

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by company insiders. Comparatively, 25.0% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor CADL or IMRX?

In the previous week, Immuneering had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 3 mentions for Immuneering and 2 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.31 beat Immuneering's score of 0.85 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend CADL or IMRX?

Candel Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 292.16%. Immuneering has a consensus price target of $14.33, indicating a potential upside of 627.58%. Given Immuneering's higher possible upside, analysts plainly believe Immuneering is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is CADL or IMRX more profitable?

Immuneering's return on equity of -79.19% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-629.29%	-173.39%
Immuneering	N/A	-79.19%	-69.08%

Which has more risk & volatility, CADL or IMRX?

Candel Therapeutics has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.

Which has higher earnings and valuation, CADL or IMRX?

Candel Therapeutics has higher earnings, but lower revenue than Immuneering. Candel Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	$120K	2,235.85	-$37.94M	-$1.34	-4.00
Immuneering	$320K	221.54	-$53.47M	-$1.96	-1.01

Does the MarketBeat Community believe in CADL or IMRX?

Immuneering received 22 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 70.91% of users gave Immuneering an outperform vote while only 65.38% of users gave Candel Therapeutics an outperform vote.

Company	Underperform	Outperform
Candel Therapeutics	Outperform Votes 17 65.38%	Underperform Votes 9 34.62%
Immuneering	Outperform Votes 39 70.91%	Underperform Votes 16 29.09%

Summary

Immuneering beats Candel Therapeutics on 11 of the 17 factors compared between the two stocks.